How Long Does TMS Take to Work? Week-by-Week Timeline

Most people undergoing standard TMS for depression begin noticing meaningful symptom changes around weeks three to four of treatment, with the strongest improvements typically emerging by weeks five and six. A standard course involves daily sessions over four to six weeks, but individual timelines vary considerably, and a sizable group of patients respond only after extended treatment beyond the typical protocol. How quickly you respond depends on the type of TMS used, the condition being treated, and a few personal factors worth understanding before you start.

What Happens in the First Two Weeks

The first one to two weeks of TMS are, for many people, uneventful in terms of noticeable mood changes. That can be discouraging if you are hoping for quick relief, but it does not mean nothing is happening. Each session delivers magnetic pulses to the left prefrontal cortex (for the standard depression protocol), and these pulses gradually alter the excitability and connectivity of brain circuits involved in mood regulation. Think of it like physical therapy for a stiff joint: the early sessions are laying the groundwork for change, even though the joint does not feel dramatically better after day three.

Some patients do report subtle shifts during this window, often in sleep quality, energy levels, or motivation rather than a clear lift in mood. These early signals can be easy to dismiss or overlook, particularly because depression itself makes it hard to track your own progress accurately. Clinicians often use standardized questionnaires at each visit to catch changes that patients themselves might not yet recognize.

Weeks Three and Four

This is when measurable clinical response typically begins for most people. In a controlled trial of TMS for treatment-resistant depression, seven out of the treated patients achieved a greater than 50% reduction in their depression scores by the end of four weeks.¹ That threshold, a halving of symptom severity, is the standard definition of “response” in depression research. Not everyone hits it by week four, but it is a common inflection point.

A large multisite trial similarly found that response rates were significantly higher with active TMS compared to sham stimulation at week four, with the gap continuing to widen through the rest of the treatment course.² If you are three weeks in and feel like the needle has barely moved, it is still too early to call TMS a failure. But if you are noticing even small improvements at this stage, that is a genuinely encouraging sign. Research on early improvement as a predictor of final outcomes found that patients who showed initial progress by this point were significantly more likely to achieve response or remission by the end of treatment.³

Weeks Five and Six

Peak efficacy tends to emerge in the final stretch of a standard course. In the same multisite trial mentioned above, remission rates with active TMS were roughly double those seen with sham treatment at week six, reaching statistical significance on two of the three depression scales used.² Remission is a higher bar than response: it means your symptoms have dropped to a level where you no longer meet diagnostic criteria for depression, not just that they have improved by a set percentage.

For many patients, the improvement curve between weeks four and six is steeper than the one leading up to week four. The cumulative effect of daily stimulation sessions appears to build on itself, with each week adding to the neural circuit changes set in motion earlier. This is one reason clinicians encourage finishing the full treatment course even if you feel substantially better by week four. Stopping early can leave potential gains on the table.

Late Responders and Extended Courses

Not everyone follows the textbook trajectory. A meaningful subset of patients show little or no improvement through the standard 36-session acute course but do respond when treatment continues beyond that point. A naturalistic study found that continuing TMS up to 72 sessions among patients who had not met response criteria by session 36 improved overall response rates.⁴

A larger study tracking over 300 patients identified four distinct response trajectories. About half the patients fell into a “slowed response” group that improved gradually throughout treatment. Roughly one in five followed a “rapid response” pattern with improvement occurring within the standard treatment length. Another one in five belonged to a “linear response, extended course” group, and those were the patients who showed considerable additional clinical improvement only after receiving extra sessions beyond the standard protocol. A small minority, about 7%, showed no meaningful response at all.⁵

The takeaway here is that a standard course works for many, but if you are a slow responder, extending treatment is worth discussing with your clinician rather than writing off TMS entirely. The evidence suggests that this “late responder” group is real and substantial, not just statistical noise.

Accelerated Protocols and the Five-Day Timeline

Standard TMS requires you to show up five days a week for four to six weeks. That is a significant time commitment, and researchers have been working on compressed alternatives. The most striking is Stanford Neuromodulation Therapy (SNT), an accelerated protocol that delivers multiple sessions per day over just five days using a form of TMS called intermittent theta burst stimulation (iTBS), guided by brain imaging to target stimulation more precisely.

In a double-blind controlled trial, SNT was associated with a remission rate of roughly 90% after five days of treatment.⁶ That number is remarkably high compared to standard protocols. A few caveats apply: the initial trial was small, the participants were carefully selected, and long-term durability data from controlled studies are still accumulating. But the result has generated enormous interest and several replication efforts. If confirmed at scale, accelerated protocols could fundamentally change the timeline question from “weeks” to “days.”

For now, most clinics still offer standard protocols, and accelerated versions like SNT are available only at specialized centers. Insurance coverage for accelerated approaches remains inconsistent. But this is a space worth watching if you are weighing TMS and the six-week commitment feels daunting.

Standard 10 Hz rTMS Versus Theta Burst Stimulation

Even within the standard treatment length, you may encounter two different session formats. Traditional high-frequency rTMS uses 10 Hz pulses and takes roughly 37 minutes per session. Intermittent theta burst stimulation (iTBS) delivers pulses in a different pattern and wraps up in about three minutes. The speed difference is dramatic, but the outcomes appear to be equivalent.

A large non-inferiority trial comparing the two approaches found that iTBS was statistically non-inferior to 10 Hz rTMS for treatment-resistant depression, with virtually identical improvements in depression scores.⁷ A separate randomized controlled trial confirmed similar response and remission rates between the two formats, with response rates around 34-37% and remission rates around 15-19% in both groups, along with comparable improvements in quality of life at six months.⁸ Early improvement predicted final outcomes equally well in both formats.³

What this means for the timeline: the week-by-week trajectory is essentially the same regardless of which session format you receive. The practical difference is that a three-minute iTBS session is far easier to fit into a workday than a 37-minute traditional session. If your clinic offers both, the choice comes down to logistics and preference rather than speed of improvement.

Factors That Influence How Quickly You Respond

Individual variation in the TMS timeline is real, and researchers have identified a few factors that help explain it.

Age is one of the better-studied predictors. Younger patients tend to respond more readily. One study found that TMS responders were significantly younger on average, and that there appeared to be a maximum threshold of age and distance from the TMS coil to the prefrontal cortex for achieving a response.⁹ The connection to distance is straightforward: as people age, the cortex tends to sit farther from the skull surface due to normal atrophy, and the magnetic field has to travel farther to reach its target. That does not mean TMS cannot work for older adults, but it may partly explain why some take longer to respond or require dose adjustments.

Treatment resistance also matters. Patients who have tried and failed multiple antidepressants tend to have more entrenched patterns of brain circuit dysfunction, which may require more sessions to shift. The severity and duration of the current depressive episode, the presence of anxiety alongside depression, and whether you are continuing medication during TMS all play roles, though the evidence on each of these is still being refined.

One factor that does not appear to influence outcomes in any meaningful way is the BDNF gene polymorphism (Val66Met), which researchers once hypothesized might predict who responds to TMS. A study specifically testing this found that while TMS significantly reduced depressive symptoms overall, the genetic variant did not predict who improved or how quickly.¹⁰ So if you have had genetic testing and were told your BDNF status might matter for TMS, the current evidence does not support that concern.

The Timeline for OCD

TMS is not only used for depression. The FDA cleared a deep TMS protocol for obsessive-compulsive disorder (OCD) in 2018, and the treatment timeline differs from the depression protocol in important ways. The OCD protocol targets a different brain region (the medial prefrontal cortex and anterior cingulate, rather than the left dorsolateral prefrontal cortex used for depression) and involves a six-week daily treatment course followed by assessment.

In the pivotal multicenter trial, patients receiving active deep TMS achieved a significantly greater reduction in OCD symptom scores compared to sham, with a response rate of about 38% versus 11% for placebo. Strikingly, response rates continued to climb after treatment ended: at a one-month follow-up, about 45% of the active treatment group met response criteria, compared to roughly 18% in the sham group.¹¹ That continued improvement after the last session is worth noting, because it suggests the brain changes triggered by TMS for OCD keep developing for weeks beyond the treatment window. If you are undergoing TMS for OCD, your clinician may tell you to reserve judgment until a month or so after completing the full course.

How Long Do the Results Last

Once TMS works, the natural next question is how long the improvement holds. Depression is a condition with high relapse rates regardless of treatment, and TMS is no exception, but the picture is more encouraging than many people expect.

A six-month open-label follow-up study of patients who had responded to TMS found that only about 10% relapsed during that period. Among the roughly 38% who experienced symptom worsening short of full relapse, the overwhelming majority, about 84%, were able to regain their improvement with additional “rescue” TMS sessions.¹² That finding introduces a useful concept: TMS does not have to be a one-and-done treatment. It can be used intermittently to head off a relapse before it fully develops.

A review of maintenance TMS studies found that most patients with treatment-resistant depression who received periodic booster sessions experienced moderate to marked ongoing benefit, with some maintaining remission for three months to as long as eight years.¹³ There is no universally agreed-upon maintenance schedule yet. Some clinics taper sessions from weekly to biweekly to monthly; others offer clusters of sessions at the first sign of symptom return. The lack of a standardized protocol has been identified as a gap in the field, with researchers noting that the absence of clear maintenance guidelines after acute TMS treatment may contribute to relapse rates in patients who initially respond well.¹⁴

If you respond to an acute course of TMS, it is worth having a specific conversation with your provider about what a maintenance plan looks like, rather than waiting until symptoms return to figure it out.

What If You Miss Sessions

The standard recommendation is five sessions per week, Monday through Friday, for the duration of treatment. In practice, most people will miss a session or two due to illness, travel, scheduling conflicts, or weather. This is a common source of anxiety for patients mid-treatment: will a missed day set back their progress?

The evidence on this point is reassuring. A study examining deviations from the five-session-per-week schedule found that modest gaps, including unexpected breaks of up to two weeks during the acute treatment phase, did not meaningfully affect final depression outcomes. Neither denser scheduling in the early weeks nor occasional missed sessions correlated with better or worse results at the end of treatment.¹⁵ So if you miss a day or even a few days in a row, there is no reason to panic. Consistency over the full course matters more than perfect attendance in any given week.

That said, the study’s findings apply to modest nonadherence, not to abandoning treatment halfway through. Completing the full prescribed number of sessions remains important; the flexibility is in how those sessions are spaced, not in whether they happen at all.

When to Reassess Expectations

Given the trajectories described above, a reasonable approach is to give standard TMS at least four weeks before drawing any conclusions, and ideally to complete the full prescribed course of six weeks before making a firm judgment. If you have shown some improvement by session 20 or so but have not yet reached response, that partial trajectory is actually a positive sign, and continuing through the full course or slightly beyond may push you over the threshold.

If you have completed a full standard course with zero improvement whatsoever, the research on trajectory groups suggests that roughly 7% of patients fall into a genuine non-response category.⁵ For those individuals, options include trying a different stimulation target, switching to a different TMS protocol, or exploring other treatments entirely. But true non-response should be distinguished from slow response, and that distinction often requires extending treatment rather than stopping it prematurely.

One practical detail worth knowing: many insurance plans approve an initial 36 sessions and may authorize additional sessions if your clinician documents partial response. If you are in that borderline zone, having your provider document your week-by-week symptom scores carefully from the beginning gives them the data they need to make the case for continuation.